1. Dienogest and the breast
- Author
-
Adolf E. Schindler, Michel Oettel, Bernd Christensen, Claudia Dr Moore, and Alexandria Henkel
- Subjects
Adult ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Mammary gland ,Endometriosis ,Urology ,Adipose tissue ,Pilot Projects ,Young Adult ,chemistry.chemical_compound ,Hormone Antagonists ,Endocrinology ,medicine ,Humans ,Nandrolone ,Breast ,Fibrocystic Breast Disease ,Breast ultrasound ,Gynecology ,medicine.diagnostic_test ,Medical treatment ,Progestogen ,business.industry ,Ultrasound ,Obstetrics and Gynecology ,medicine.disease ,medicine.anatomical_structure ,Dienogest ,chemistry ,Female ,Ultrasonography, Mammary ,business - Abstract
In a clinical pilot study, 21 women with endometriosis have been primarely treated with dienogest 2 × 10 mg daily p.o. for 24 weeks. Besides the effect on endometriosis the action of such high-dose progestogen treatment on the breast was evaluated by breast ultrasound prior to medication and at 24 weeks of medical treatment. In all women, a significant size reduction of the mammary gland (p < 0.023) and regression of mastopathic changes were observed. There was a non-significant reduction (p = 0.089) of the maximum diameter of the ducts. The portion of the fatty tissue increased slightly, but not significantly (p = 0.348).
- Published
- 2009